BOK Financial Private Wealth Inc. significantly reduced its stake in Johnson & Johnson by 35.7% in Q3, selling 4,699 shares. Despite this, other institutional investors, such as AustralianSuper and the Treasurer of North Carolina, increased their holdings, with institutional ownership of JNJ standing at approximately 69.55%. Key positive catalysts for J&J include the FDA approval of a once-monthly dosing for RYBREVANT FASPRO and continued strong growth in its MedTech segment, while legal risks from talc verdicts remain a negative factor.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
BOK Financial Private Wealth Inc. Lowers Holdings in Johnson & Johnson $JNJ
BOK Financial Private Wealth Inc. significantly reduced its stake in Johnson & Johnson by 35.7% in Q3, selling 4,699 shares. Despite this, other institutional investors, such as AustralianSuper and the Treasurer of North Carolina, increased their holdings, with institutional ownership of JNJ standing at approximately 69.55%. Key positive catalysts for J&J include the FDA approval of a once-monthly dosing for RYBREVANT FASPRO and continued strong growth in its MedTech segment, while legal risks from talc verdicts remain a negative factor.